Félix Arias Gabasa

Highgrowth Partners SGECR SA, also known as HG BcnHighgrowth, is an independent Barcelona-based venture capital firm. HG BcnHighgrowth was established in 2008 through the absorption of BCN Emprèn SCR SA (also known as Barcelona Emprèn) by Highgrowth Partners SGECR SA, established in 2001. Both firms pioneered venture capital investment management in the Catalonia region of northern Spain. HG BcnHighgrowth provides business consulting services and invests a combination of public and private funds. Their lead investors include regional entities such as the Barcelona City Council and the Catalan Finance Institute (ICF), as well as the European Investment Fund and Spanish mutual assurance societies, corporations and financial institutions. Their clients are Spanish institutions and private individuals.

Archivel Farma SL provides research and development services to the pharmaceutical sector. It focuses on TB, more specifically, on the treatment of the latent TB infection diseases. The firm is association with the Germans Trias i Pujol Research Institut of Health Sciences and the Germans Trias i Pujol University Hospital has developed RUTI, the first therapeutic vaccine against TB. The company was founded in 2005 by José Martínez, Pere-Joan Cardona i Iglèsias, Jaume Amat i Reira and Isabel Amat i Riera and is headquartered in Badalona, Spain.

VozTelecom OIGAA360 SA is a holding company, which engages in the provision of cloud-based telecommunications solutions for small and medium-scale enterprises. Its services include fixed and mobile telephony, broadband internet, and virtual private branch exchange. The company was founded by Xavier Casajoana, Jesus Rodriguez, and Gines Gomez on February 10, 2003 and is headquartered in Cerdanyola del Valles, Spain.

Nekko Capital SGEIC SA is an Independent Venture Capital firm founded in 2015 by Félix Arias Gabasa, Mercè Tell García and Santiago Pi Figueras Valls. Nekko Capital SGEIC SA is headquartered in Barcelona with additional offices in Madrid and London.